Could chelation therapy with deferoxamine enhance the percentage of responders to interferon therapy in chronic hepatitis C?
Leonardi
S
S
Department of Pediatrics, University of Catania, Italy.
Musumeci
S
S
D015913:Chelation Therapy; D002908:Chronic Disease; D003131:Combined Modality Therapy; D003676:Deferoxamine / Q000627:therapeutic use*; D004357:Drug Synergism; D005293:Ferritins / Q000097:blood / Q000187:drug effects; D006526:Hepatitis C / Q000097:blood / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D011994:Recombinant Proteins; D012074:Remission Induction; D013789:Thalassemia / Q000097:blood / Q000150:complications / Q000628:therapy
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D005293:Ferritins; D003676:Deferoxamine